Skip to main content

Table 3 Haplotypes of the tested genes concerning the analysed phenotypes in HD patients

From: ENHO, RXRA, and LXRA polymorphisms and dyslipidaemia, related comorbidities and survival in haemodialysis patients

Gene

Polymorphisms

Haplotype

Freq.

Case, Control Frequencies

Chi Square

P Value

Pcorr Valuea

OR (95% CI), p valueb

OR (95% CI), p valuec

myocardial infarction = CASES, without myocardial infarction = CONTROLS

LXRA

rs2279238_rs7120118

GT

0.693

0.646, 0.705

4.810

0.028

0.078

reference

0.761 (0.596–0.971), 0.028

 

AC

0.168

0.165, 0.169

0.036

0.849

0.993

1.068 (0.777–1.468), 0.685

0.973 (0.713–1.328), 0.863

 

GC

0.139

0.190, 0.126

9.791

0.002

0.005*

1.645 (1.202–2.252), 0.002

1.624 (1.194–2.208), 0.002*

rs11039155_rs2279238_rs7120118

GGT

0.692

0.646, 0.704

4.565

0.033

0.098

reference

0.771 (0.602–0.989), 0.040

 

AAC

0.160

0.157, 0.160

0.033

0.857

1.000

1.064 (0.769–1.472), 0.709

0.976 (0.710–1.342), 0.883

 

GGC

0.137

0.184, 0.124

8.828

0.003

0.005*

1.598 (1.162–2.198), 0.004

1.580 (1.156–2.159), 0.004*

dyslipidaemia by K/DOQI criteria = CASES, without dyslipidaemia by K/DOQI criteria = CONTROLS

ENHO

rs72735260_rs2281997

GC

0.582

0.549, 0.619

8.786

0.003

0.008*

reference

0.756 (0.624–0.917), 0.004*

 

GT

0.278

0.314, 0.238

12.299

5.0E-4

0.001*

1.483 (1.191–1.846), 0.0004

1.471 (1.189–1.819), 0.0004*

 

TC

0.133

0.128, 0.138

0.434

0.5101

0.773

1.045 (0.785–1.390), 0.7645

0.921 (0.698–1.215), 0.562

atherogenic dyslipidaemia = CASES, without atherogenic dyslipidaemia = CONTROLS

ENHO

rs72735260_rs2281997

GC

0.582

0.618, 0.544

9.824

0.002

0.004*

reference

1.343 (1.109–1.627), 0.003*

 

GT

0.278

0.244, 0.314

10.532

0.001

0.004*

0.687 (0.553–0.854), 0.0007

0.704 (0.570–0.869), 0.001*

 

TC

0.133

0.132, 0.133

0.002

0.968

1.000

0.880 (0.661–1.172), 0.3825

0.994 (0.753–1.312), 0.966

LXRA

rs11039155_rs2279238

GG

0.827

0.803, 0.853

7.496

0.0062

0.009*

reference

0.714 (0.550–0.927), 0.011*

 

AA

0.161

0.182, 0.137

6.433

0.0112

0.028*

1.401 (1.079–1.819), 0.0111

1.401 (1.079–1.819), 0.011*

rs2279238_rs7120118

GT

0.693

0.676, 0.711

2.423

0.1196

0.249

reference

0.846 (0.689–1.039), 0.110

 

AC

0.168

0.190, 0.145

6.363

0.0117

0.029*

1.386 (1.069–1.797), 0.0135

1.391 (1.077–1.796), 0.011*

 

GC

0.139

0.134, 0.145

0.424

0.5151

0.795

0.978 (0.741–1.291), 0.8776

0.819 (0.699–1.207), 0.541

rs11039155_rs2279238_rs7120118

GGT

0.692

0.676, 0.708

2.094

0.1479

0.416

reference

0.873 (0.709–1.074), 0.199

 

AAC

0.160

0.180, 0.137

5.942

0.0148

0.023*

1.369 (1.049–1.785), 0.0204

1.384 (1.065–1.798), 0.015*

 

GGC

0.137

0.129, 0.145

0.917

0.3382

0.750

0.935 (0.706–1.236), 0.6351

0.882 (0.669–1.162), 0.370

  1. Significant P-values are indicated using an asterisk
  2. aThe p-value was calculated using the permutation test and 1000 permutations
  3. bThe most common haplotype was used as the reference
  4. cAll other haplotypes pooled together were used as the reference
  5. Only ENHO and LXRA haplotypes yielded significant results after correction
Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us